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ABSTRACT	  	  45 
	  46 
Background:	   Patients	   with	   homozygous	   intronic	   pseudoexon	   GH	   receptor(GHR)	  47 
mutations(6Ψ)	  have	  growth	  hormone	  Insensitivity(GHI)	  (growth	  failure,	  IGF1	  deficiency	  48 
and	   normal/elevated	   serum	   GH).	   We	   report	   9	   patients	   in	   addition	   to	   previously	  49 
described	  11	  GHR	  6Ψ	  patients	  and	  their	  responses	  to	  rhIGF1	  therapy.	  	  50 
Methods:	   20	   patients	   (12	   males,	   11	   families,	   mean	   age	   4.0±2.2yrs)	   were	   diagnosed	  51 
genetically	   in	   our	   centre.	   Phenotypic	   data	   and	   responses	   to	   rhIGF1	   treatment	   were	  52 
provided	  by	  referring	  clinicians.	  Continuous	  parametric	  variables	  were	  compared	  using	  53 
student	  t-­‐test	  or	  ANOVA.	  54 
Results:	  10/20(50%)	  had	  typical	  facial	  features	  of	  GHI,	  19/20(95%)	  from	  consanguineous	  55 
families	  and	  18/20(90%)	  of	  Pakistani	  origin.	  At	  diagnosis,	  mean	  height	  SDS:-­‐4.1	  ±	  0.95,	  56 
IGF1	  SDS	  :-­‐2.8	  ±	  1.4;	   IGFBP3	  SDS	  :	   -­‐3.0	  ±	  2.1	  and	  mean	  basal	  and	  peak	  GH	  levels:	  11.9	  57 
µg/L	  and	  32.9	  µg/L,	  respectively.	  1/12	  who	  had	  IGF1	  generation	  test,	  responded	  (IGF1:	  58 
132	   to	   255	  ng/ml).	   15/20	   (75%;	   11M)	   received	   rhIGF1(mean	  dose	  114	  micrograms/kg	  59 
twice	   daily,	   mean	   duration:	   5.3	   ±	   2.5yrs).	   Mean	   baseline	   height	   velocity	   of	   4.7	   ±	  60 
1.1cm/yr	   increased	   to	  7.4	  ±	  1.8cm/yr(p=0.001)	  during	  Year	  1	  of	   therapy.	  Year	  3	  mean	  61 
height	  SDS	  (-­‐3.2	  ±	  1.0)	  was	  higher	  than	  pre-­‐treatment	  height	  SDS	  (-­‐4.3	  ±	  0.8)	  (p=0.03).	  62 
Mean	  cumulative	  increase	  in	  height	  SDS	  after	  year	  5	  was	  1.4	  ±	  0.9.	  Difference	  between	  63 
target	  height(TH)SDS	  and	  adult	  or	   latest	  height	   SDS	  was	   less	   than	   that	  of	   TH	  SDS	  and	  64 
pretreatment	  height	  SDS	  (2.1±1.2	  vs	  3.0±0.8;	  p=0.02).	  	  65 
 4 
Conclusion:	  In	  addition	  to	  phenotypic	  heterogeneity	  in	  the	  cohort,	  there	  was	  mismatch	  66 
between	  clinical	  and	  biochemical	  features	  in	  individual	  patients	  with	  6Ψ	  GHR	  mutations.	  67 






















	  Growth	  Hormone	  Insensitivity	  (GHI)	   is	  characterised	  by	  growth	  failure,	   IGF1	  deficiency	  89 
and	  normal	  or	  elevated	  serum	  GH.	  A	  continuum	  of	  genetic,	  phenotypic,	  and	  biochemical	  90 
abnormalities	   has	   been	   established,	   associated	   with	   defects	   in	   linear	   growth1.	  91 
Monogenic	  defects	  in	  the	  GH-­‐IGF1	  axis	  leading	  to	  GHI	  have	  been	  discovered	  in	  GHR2,	  3,	  92 
STAT5B4,	  5,	  IGFALS6,	  PAPPA27	  and	  IGF18	  genes.	  	  93 
	  94 
Within	   the	   growth	   hormone	   receptor	   (GHR)	   gene,	   more	   than	   seventy	   missense,	  95 
nonsense	   and	   splice	   mutations	   in	   over	   two	   hundred	   and	   fifty	   patients	   have	   been	  96 
described1.	   The	  majority	   of	  GHR	   defects	   are	   homozygous	   or	   compound	   heterozygous	  97 
mutations	   in	   the	   region	   encoding	   the	   GHR	   extracellular	   domain,	   responsible	   for	   GH	  98 
binding9,10.	  GHR	  mutations	  cause	  a	  continuum	  of	  phenotypes	  ranging	  from	  severe,	  with	  99 
classical	   GHI	   facies	   and	   undetectable	   IGF1	   levels11,12,	   to	   mild	   with	   no	   dysmorphic	  100 
features.	  The	  latter	  is	  commonly	  associated	  with	  heterozygous	  dominant	  negative13,14	  or	  101 
compound	  heterozygous	  GHR	  mutations15.	  	  102 
	  103 
The	  intronic	  GHR	  pseudoexon	  mutation	  (6Ψ)	  was	  first	  described	  in	  2001	  in	  four	  siblings	  104 
with	  mild	  GHI	  from	  a	  highly	  consanguineous	  Pakistani	  family.	  This	  point	  mutation	  (base	  105 
change	  A-­‐1	  to	  G-­‐1)	  in	  intron	  6	  leads	  to	  aberrant	  splicing	  and	  activation	  of	  a	  pseudoexon	  106 
sequence	  causing	  a	  spectrum	  of	  clinical	  and	  biochemical	  abnormalities16.	  The	  inclusion	  107 
of	   an	  additional	   108	  bases	  between	  exons	  6	   and	  7	  of	   the	  GHR	  gene	   translates	   to	   the	  108 
insertion	  of	  36	  new	  amino	  acids	  within	  the	  extracellular	  domain	  and	  impaired	  function	  109 
 6 
of	  the	  mutant	  GHR	  protein17.	  In	  2007,	  a	  further	  seven	  6Ψ	  patients	  were	  reported18	  with	  110 
more	  severe	  GHI	  phenotypes	  and	  heights	  as	  low	  as	  -­‐6.0	  SDS.	  111 
	  112 
We	   have	   identified	   nine	   further	   6Ψ	   subjects	   and	   report	   the	   clinical	   and	   biochemical	  113 
features	  in	  the	  cohort	  of	  twenty	  patients.	  Additionally,	  we	  describe	  growth	  responses	  to	  114 
rhIGF1	  therapy,	  which	  has	  not	  previously	  been	  reported.	  	  	  115 
	  116 
SUBJECTS	  AND	  METHODS	  117 
	  	  118 
Patients	  119 
Between	  2001	  and	  2014,	  20	  patients	  (11	  families,	  10	  with	  parental	  consanguinity)	  were	  120 
diagnosed	  with	  the	  intronic	  GHR	  6Ψ	  mutation	  in	  our	  centre.	  There	  were	  12	  males	  and	  8	  121 
females,	  mean	  age	  at	  presentation	  was	  4.0	  ±	  2.2	  yrs	   (range	  0.7-­‐13.0	  yrs).	  The	  patients	  122 
were	  investigated	  in	  5	  UK	  and	  1	  US	  paediatric	  endocrinology	  centres.	  	  123 
	  124 
Clinical,	  auxological	  and	  biochemical	  data	  125 
The	  patients	  were	   investigated	  at	   their	   home	   institutions	   and	   the	   referring	  physicians	  126 
completed	   a	   proforma	   detailing	   the	   clinical	   and	   biochemical	   details	   at	   the	   time	   of	  127 
sending	  the	  DNA	  sample	  for	  genetic	  analysis.	  Height	  measurements	  were	  obtained	  using	  128 
a	  wall-­‐mounted	   stadiometer.	   Pubertal	   staging	  was	   done	   using	   Tanner	   stages19,20.	   Pre-­‐129 
pubertal	  patients	  were	  Tanner	  stage	  1	  genital	  development	  or	  breast	  development	  for	  130 
boys	  and	  girls,	   respectively.	  Pubertal	  patients	  were	  Tanner	  stage	  2	  or	  above	  genital	  or	  131 
 7 
breast	  development	  for	  boys	  or	  girls,	  respectively.	  132 
	  Birth	  weight,	  parental	  height,	  height	  and	  BMI	  values	  were	  expressed	  as	  SDS	  according	  133 
to	  the	  appropriate	  UK-­‐WHO	  growth	  national	  standards21,22,23.	  Biochemical	  investigations	  134 
included:	   basal	   and/or	   peak	  GH,	   basal	   IGF1	   and	   peak	   IGF1	   during	   an	   IGF1	   generation	  135 
test	   (IGFGT)	   and	   basal	   IGFBP-­‐3	   levels.	   Basal	   GH	   levels	   and	   GH	   provocation	   tests	  136 
(glucagon,	   clonidine	   or	   arginine	   stimulation	   tests	   or	   insulin	   tolerance	   tests)	   were	  137 
performed	  in	  the	  local	  centres.	  IGF1	  and	  IGFBP3	  values	  were	  expressed	  as	  SDS	  based	  on	  138 
the	  age	  and	  sex	  appropriate	  ranges	  provided	  by	  the	  host	  institution.	  Where	  serum	  IGF1	  139 
was	  undetectable	   (less	   than	   the	   lower	   limit	  of	   the	  assay)	   (n=7),	   the	   lowest	  detectable	  140 
SDS	  was	  calculated	  for	  statistical	  analysis.	   IGFGTs	  were	  performed	  locally	  as	  previously	  141 
published	   (dose	  of	  GH	  0.033	  mg/kg	  body	  weight	  daily	   for	   4	  days)	   24,25.	   An	   increase	   in	  142 
IGF1	  level	  of	  >15	  ng/ml	  between	  basal	  and	  peak	  values	  in	  the	  IGFGT	  was	  considered	  a	  143 
positive	  response	  24.	  144 
	  145 
Therapy	  with	  rhIGF1	  146 
Patients	  were	   treated	  with	   recombinant	  human	   IGF1	   (rhIGF1)	  at	   their	   local	  centres	  by	  147 
the	  referring	  paediatric	  endocrinologists.	  Auxology	  data	  (height	  and	  weight)	  at	  different	  148 
time	  points	  of	  treatment	  and	  the	  relevant	  clinical	  data	  (e.g.	  pubertal	  stage,	  concomitant	  149 
treatment	  etc)	  were	  provided	  by	  the	  referring	  clinicians.	  Auxology	  data	  were	  excluded	  150 




Genetic	  analysis	  	  	  154 
Genomic	  DNA	  was	  isolated	  from	  peripheral	  blood	  leukocytes	  (Qiagen	  DNeasy	  Kit).	  	  Each	  155 
exon	  of	   the	  GHR,	  plus	   the	  pseudoexon	   (6Ψ),	   including	   their	   intronic	  boundaries,	  were	  156 
amplified	   by	   PCR	   using	   specific	   primers	   (primer	   sequences	   available	   on	   request).	   PCR	  157 
products	   were	   visualized	   on	   1%	   agarose	   gel	   and	   sent	   subsequently	   for	   Sanger	  158 
sequencing.	   Sanger	   sequencing	  was	   performed	  by	   the	   Barts	   and	   the	   London	  Genome	  159 
Centre	   (http://www.smd.qmul.ac.uk/gc/)	   or	   GATC	   Biotech	   (https://www.gatc-­‐160 
biotech.com).	  161 
	  162 
Ethical	  approval	  	  163 
Informed	  written	   consent	   for	   genetic	   research	   and	   publication	   of	   their	   clinical	   details	  164 
and	   clinical	   images	  was	   obtained	   from	   patients	   and/or	   their	   parents.	   	   The	   study	  was	  165 
approved	  by	  the	  Health	  Research	  Authority,	  East	  of	  England	  -­‐	  Cambridge	  East	  Research	  166 
Ethics	  Committee	  (REC	  reference:	  17/EE/0178).	  	  167 
	  168 
Statistical	  analysis	  	  169 
For	  responses	  to	  rhIGF1	  therapy,	  the	  primary	  end-­‐point	  was	  height	  velocity	  (HV)	  at	  the	  170 
end	  of	  the	  first	  year	  of	  treatment.	  Pearson	  correlation	  coefficient	  assessed	  the	  following	  171 
correlations:	  height	  SDS	  and	  IGF1	  SDS,	  height	  SDS	  and	  IGFBP-­‐3	  SDS,	  first	  year	  HV	  and	  age	  172 
at	  initiation	  of	  treatment,	  sex	  of	  patient,	  baseline	  height	  SDS	  and	  baseline	  IGF1	  SDS.	  173 
Pre-­‐treatment	   HV/height	   SDS	   and	   HV/height	   SDS	   during	   years	   1,	   2	   and	   3	   of	   rhIGF1	  174 
treatment	   were	   compared	   with	   ANOVA	   with	   Bonferroni	   correction	   for	   multiple	  175 
 9 
comparisons.	  The	  difference	  between	  target	  height	  SDS	  and	  pre-­‐treatment	  height	  SDS	  176 
was	  compared	  to	  the	  difference	  between	  target	  height	  SDS	  and	  adult	  height/height	  at	  177 
latest	   assessment	   by	   unpaired	   two-­‐tailed	   student’s	   t-­‐	   test.	   A	   p	   value	   of	   ≤	   0.05	   was	  178 




Phenotypic	  details	  	  183 
Clinical	   and	   biochemical	   details	   are	   shown	   in	   Table	   1.	   The	   mean	   height	   SDS	   of	   the	  184 
subjects	  was	  -­‐4.1	  ±	  0.95	  (range-­‐1.7	  to	  -­‐5.9),	  mean	  IGF1	  SDS	  was	  -­‐2.8	  ±	  1.4	  (range	  -­‐1.0	  to	  -­‐185 
6.8);	  mean	  IGFBP-­‐3	  SDS	  was	  -­‐3.0	  ±	  2.1	  (range	  -­‐0.6	  to	  -­‐8.9);	  mean	  basal	  GH	  level	  was	  11.9	  186 
µg/L	  (range	  0.1	  to	  19.3)	  and	  mean	  peak	  GH	  level	  was	  32.9	  µg/L	  (range	  10.0	  to	  >40).	  	  Ten	  187 
out	   of	   20	   (50%)	   patients	   had	   classical	   facial	   features	   of	   GHI	   (defined	   as	   mid-­‐facial	  188 
hypoplasia,	  depressed	  nasal	  bridge	  and	  prominent	  forehead	  26);	  19/20	  (95%)	  were	  from	  189 
consanguineous	   families	   and	   18/20	   (90%)	   are	   of	   Pakistani	   origin.	   Consistent	   with	   the	  190 
previous	  results,	  wide	  ranges	  of	  short	  stature	  and	  biochemical	  abnormalities	  are	  noted.	  	  191 
	  192 
Variable	  phenotypic	  and	  biochemical	  features	  between	  and	  within	  kindreds	  193 
Patient	  A6	  is	  related	  to	  the	  previously	  described	  highly	  consanguineous	  Pakistani	  family	  194 
(A1-­‐A5)16,18.	  Unlike	  the	  other	  family	  members,	  she	  had	  facial	  features	  of	  GHI	  with	  mid-­‐195 
facial	  hypoplasia,	  depressed	  nasal	  bridge	  and	  prominent	  forehead.	  Patients	  A2	  and	  A5,	  196 
from	  the	  same	  family,	  had	  similar	  or	  more	  severe	  degrees	  of	  short	  stature	  (height	  SDS	  -­‐197 
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5.4	   and	   -­‐4.4,	   respectively)	   but,	   lacked	   abnormal	   facial	   features.	   Patient	   B	   had	   a	  198 
moderate	  clinical	  phenotype,	  height	  -­‐5.6	  SDS	  but	  IGF1	  SDS	  was	  only	  slightly	  subnormal	  (-­‐199 
2.3	  SDS).	  Families	  G	  &	  H	  (2	  pairs	  of	  siblings),	   showed	  more	  phenotypic	  variability	  with	  200 
moderate	   short	   stature	   (height	   SDS	   -­‐3.4	   to	   -­‐4.7),	   relatively	  mild	   biochemical	   features	  201 
(IGF1	  SDS	  -­‐2.3	  to	  -­‐3.1)	  and	  variable	  peak	  GH	  (18	  to	  >33	  μg/L)	  but	  all	  had	  classical	  facial	  202 
GHI	  features.	  Similarly,	  patients	  I	  and	  K	  had	  mild	  to	  moderate	  phenotypes	  and	  abnormal	  203 
facial	   features.	   In	   contrast,	   families	   D	   &	   E	   (2	   pairs	   of	   siblings)	   and	   patient	   F	   had	  204 
moderate	   clinical	   and	   biochemical	   features,	   similar	   to	   patients	   A6,	   I	   and	   K	   but	   lacked	  205 
facial	   abnormalities.	   Finally,	   patient	   J	   (distant	   cousin	   of	   A5)	   had	   typical	   GHI	   facial	  206 
features	  and	  a	  severe	  biochemical	  phenotype	  but	  height	  was	  moderately	   low	  (height	  -­‐207 
4.0	  SDS).	  208 
	  209 
IGF1	  generation	  test	  (IGFGT)	  210 
Twelve	   out	   of	   20	   subjects	   underwent	   IGFGT	   (Table	   2).	   Only	   1	   patient	   (D2)	   showed	   a	  211 
response,	  with	  increase	  of	  IGF1	  from	  132	  to	  255	  ng/ml.	  His	  height	  was	  -­‐4.9	  SDS	  and	  he	  212 
had	  normal	  facial	  features	  (Figure	  1).	  213 
	  214 
Relationships	  between	  height	  and	  IGF1	  and	  IGFBP-­‐3	  215 
There	  was	  no	  positive	  correlation	  between	  height	  SDS	  and	  basal	  IGF1	  SDS	  or	  between	  216 
height	  SDS	  and	  IGFBP-­‐3	  SDS.	  217 
	  218 
Responses	  to	  rhIGF1	  therapy	  	  219 
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15	  out	  of	  20	  patients	  (75%;	  11M)	  received	  rhIGF1	  treatment.	  The	  mean	  age	  at	  initiation	  220 
of	   rhIGF1	   in	   all	   subjects	  was	   9.0	   ±	   2.7	   yrs	   (range	   5.7-­‐15.3)	   and	   the	  mean	   duration	   of	  221 
treatment	  was	  5.3	  ±	  2.5	  yrs	   (range	  1.5-­‐7.6).	  The	  mean	  dose	  of	   rhIGF1	  was	  114	   (range	  222 
110-­‐130)	   micrograms/kg	   twice	   a	   day.	   5	   of	   15	   patients	   had	   received	   combination	  223 
rhIGF1/IGFBP-­‐3	  therapy	  as	  part	  of	  a	  previous	  study27.	  Of	  these	  5	  patients,	   in	  the	  first	  5	  224 
years	  of	  treatment,	  1	  had	  >6	  months	  interrupted	  rhIGF1	  treatment	  between	  years	  2	  and	  225 
3,	  the	  rest	  had	  uninterrupted	  rhIGF1	  therapy.	  10	  of	  15	  patients	  were	  treatment-­‐naïve.	  In	  226 
this	   group,	   5	   patients	   had	   treatment	   gaps	   of	   >6	   months	   between	   years	   4	   and	   5	   of	  227 
therapy.	   Height	   outcomes	   were	   analysed	   at	   baseline	   (n=15),	   year	   1	   (n=15),	   year	   2	  228 
(n=14),	  and	  year	  3	  (n=10)	  (Figures	  2	  and	  3).	  	  229 
	  230 
Mean	   cumulative	   height	   SDS	   change	   over	   5	   years	   of	   treatment	   was	   calculated	   in	   9	  231 
patients	  (4	  previously	  treated	  and	  5	  treatment-­‐naïve).	  3	  of	  15	  patients	  were	  pubertal	  at	  232 
the	   start	   of	   rhIGF-­‐I	   therapy	   and	   were	   concomitantly	   commenced	   on	   GnRH	   analogue	  233 
therapy.	  	  234 
	  235 
Change	  in	  height	  velocity	  (HV)	  during	  years	  1,	  2	  and	  3	  of	  rhIGF1	  therapy	  236 
Baseline	  mean	  HV	  was	  4.7	  ±	  1.1	  cm/yr	  and	  increased	  to	  7.4	  ±	  1.8	  cm/yr	  during	  the	  first	  237 
year	  of	  treatment	  (p=0.001)	  (Figure	  2).	  	  The	  first	  year	  HV	  in	  the	  treatment-­‐naïve	  patients	  238 
(n=10)	  was	  7.9	  ±	  1.6	  cm/yr,	  which	  was	  comparable	  to	  HV	  in	  the	  previously	  treated	  group	  239 
(n=5)	   (6.3	   ±	   1.9	   cm/yr;	   p=0.12).	   There	   was	   no	   significant	   correlation	   between	   year	   1	  240 
mean	  HV	  or	  year	  1	  mean	  HV	  SDS	  with	  sex,	  age	  at	  rhIGF1	  initiation,	  baseline	  height	  SDS,	  241 
 12 
baseline	  BMI	  SDS	  or	  baseline	  IGF1	  SDS.	  	  242 
	  243 
Mean	  HV	  during	  the	  years	  2	  and	  3	  of	  rhIGF1	  treatment	  were	  5.6	  ±	  1.8	  cm/yr	  and	  5.3	  ±	  244 
1.9	  cm/yr,	  respectively.	  Although	  these	  values	  were	  above	  baseline,	  the	  difference	  was	  245 
not	   significant	   (p=0.11	   and	   0.36,	   respectively)	   (Figure	   2).	   In	   treatment-­‐naïve	   group,	  246 
there	   were	   also	   no	   significant	   differences	   in	   mean	   HV	   at	   year	   2	   and	   3	   compared	   to	  247 
baseline.	  	  248 
	  249 
Change	  in	  height	  SDS	  during	  years	  1,	  2	  and	  3	  of	  rhIGF1	  therapy	  250 
Mean	  height	  SDS	  at	  year	  1	  and	  year	  2	  of	  rhIGF1	  therapy	  were	  -­‐3.8	  ±	  0.9	  and	  -­‐3.4	  ±	  1.0,	  251 
respectively.	   These	   values	   were	   not	   significantly	   different	   from	   pre-­‐treatment	   height	  252 
SDS	  (-­‐4.3	  ±	  0.8,	  Figure	  3).	   In	  the	  treatment-­‐naïve	  group,	  there	  were	  also	  no	  significant	  253 
differences	  in	  height	  SDS	  at	  year	  1	  and	  2	  compared	  to	  baseline.	  Mean	  height	  SDS	  at	  year	  254 
3	  of	  treatment	  (-­‐3.2	  ±	  1.0)	  was	  however,	  significantly	  higher	  than	  pre-­‐treatment	  height	  255 
SDS	  (p=0.03)	  (Figure	  3).	  In	  the	  naïve	  group,	  mean	  height	  SDS	  also	  increased	  significantly	  256 
from	  -­‐4.1	  ±	  0.8	  at	  baseline	  to	  -­‐2.9	  ±	  1.0	  at	  year	  3	  (p=0.01).	  The	  mean	  cumulative	  change	  257 
in	   height	   SDS	   at	   year	   5	   of	   continuous	   treatment	   in	   9	   treated	   patients	   was	   1.4	   ±	   0.9	  258 
(range	  0.2	  to	  3.2).	  	  259 
	  260 
Adult	  height	  (AH)	  at	  discontinuation	  of	  rhIGF1	  therapy	  and	  height	  at	   latest	  assessment	  261 
(LH)	  for	  patients	  with	  ongoing	  rhIGF1	  therapy	  262 
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12	  (8M)	  of	  15	  treated	  patients	  have	  completed	  linear	  growth	  (adult	  height,	  AH).	  7	  of	  12	  263 
were	  naive	  to	  rhIGF1	  therapy	  and	  5	  had	  received	  rhIGF1/IGFBP-­‐3	  therapy	  previously	  27.	  264 
The	  mean	  AH	  SDS	  was	  -­‐3.3	  ±	  1.3	  SDS	  (-­‐5.7	  to	  -­‐1.8),	  compared	  to	  pre-­‐treatment	  height	  265 
SDS	  (-­‐4.3	  ±	  0.9	  SDS;	  -­‐5.9	  to	  -­‐3.2)	  (p=0.05).	  Mean	  AH	  in	  the	  treatment-­‐naïve	  group	  (n=7)	  266 
was	  -­‐3.1	  ±	  1.3	  SDS	  (-­‐5.7	  to	  -­‐1.8)	  and	  this	  was	  also	  higher	  than	  the	  pre-­‐treatment	  mean	  267 
height	  SDS	  -­‐4.1±	  0.9	  SDS	  (-­‐5.9	  to	  -­‐3.2)	  (p=0.08).	  	  The	  individual	  growth	  curves	  for	  8	  male	  268 
and	  4	  female	  patients	  are	  shown	  in	  Figures	  4a	  and	  4b,	  respectively.	  	  269 
	  270 
In	  3	  of	  15	  patients	  who	  remained	  on	  rhIGF1	  therapy	  (all	  naïve	  to	  rhIGF1,	  ages	  at	  latest	  271 
assessment	  9.2	  yrs,	  11.0	  yrs	  and	  12.3	  yrs),	  LH	  was	  -­‐3.1	  ±	  0.1	  SDS	  (-­‐3.2	  to	  -­‐3.0)	  and	  this	  272 
was	  higher	  than	  pre-­‐treatment	  height	  SDS	  -­‐4.2	  ±	  0.6	  SDS	  (-­‐4.8	  to	  -­‐3.6)	  (p=0.03).	  	  273 
	  274 
The	  difference	  between	  target	  height	  (TH)	  SDS	  and	  AH/LH	  SDS	  was	  less	  than	  that	  of	  TH	  275 
SDS	  and	  pretreatment	  height	  SDS	  (2.1±1.2	  vs	  3.0±0.8;	  p=0.02)	  (Figure	  5).	  276 
	  277 
Heights	  in	  the	  untreated	  patients	  278 
In	  the	  3	  untreated	  patients,	  AH	  SDS	  was	  -­‐3.5	  and	  -­‐5.0	  and	  LH	  SDS	  (at	  age	  of	  5.0	  yrs)	  was	  -­‐279 




It	   is	   well	   established	   that	   growth	   hormone	   receptor	   (GHR)	   gene	   mutations	   cause	   a	  284 
 14 
continuum	   of	   phenotypes,	   even	   within	   families	   with	   the	   same	   mutation11,29,30.	   Our	  285 
cohort	   of	   20	   patients	  with	   the	   rare	   intronic	  GHR	   pseudoexon	  mutation	   (6Ψ)	   provides	  286 
further	   insights	   into	   the	   phenotypic	   variation	   of	   GHI	   caused	   by	   a	   single	   mutation.	  287 
Consistent	  with	  the	  previous	  report	  18,	  the	  spectrum	  of	  phenotypic	  variability	  is	  marked.	  288 
The	  6Ψ	  GHR	  mutation	  leads	  to	  aberrant	  splicing,	  resulting	  in	  an	  aberrant	  splice	  product	  289 
of	   the	  GHR	   gene.	   This	   splicing	   process	   is	   highly	   variable,	   hence	   variable	   quantities	   of	  290 
normal	  and	  abnormal	   transcripts	  will	   be	  generated.	  Gene	   transcript	  heterogeneity	   i.e.	  291 
the	  ratio	  of	  abnormal	  (mutated	  GHR)	  to	  normal	  (wild	  type	  GHR)	  proteins	  and	  the	  role	  of	  292 
genetic	  and	  environmental	  factors	  in	  defining	  this	  ratio,	  have	  been	  postulated	  to	  play	  a	  293 
role	   in	   the	   clinical	   variability	   16,18.	   However	   this	   needs	   to	   be	   further	   explored	   in	   6Ψ	  294 
patients	   with	   a	   range	   of	   phenotypes	   to	   establish	  whether	   patients	   with	  more	   severe	  295 
phenotypes	  have	  relatively	  more	  mutant	  protein	  transcript.	  296 
	  297 
The	  characteristic	  facial	  features	  seen	  in	  severe	  GHI,	  namely,	  mid-­‐facial	  hypoplasia	  and	  298 
prominent	   forehead,	   reflect	   the	   underdevelopment	   of	   the	   facial	   bones	   secondary	   to	  299 
IGF1	   deficiency12,31.	   As	   such,	   it	   has	   been	   proposed	   that	   the	   degree	   of	   craniofacial	  300 
changes	   are	   likely	   to	   be	  more	   prominent	   in	   patients	   with	   more	   severe	   short	   stature	  301 
and/or	  a	  greater	  degree	  of	  IGF1	  deficiency31,32.	  However,	  in	  our	  cohort,	  the	  presence	  or	  302 
absence	   of	   abnormal	   facial	   features	   did	   not	   correlate	  with	   either	   the	   degree	   of	   short	  303 
stature	  or	  the	  biochemical	  abnormalities.	  	  304 
	  305 
Previous	  studies	  have	  shown	  that	  serum	  IGF1	  and	  IGFBP-­‐3	   levels	  correlate	  with	  height	  306 
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SDS	  values	  in	  patients	  with	  GHR	  mutations	  causing	  severe	  GHI	  i.e.	  the	  more	  severe	  the	  307 
IGF1	  deficiency	  (IGFD),	  the	  more	  severe	  the	  height	  deficiency29.	  The	  mismatch	  between	  308 
clinical	   phenotype	   (i.e.	   degree	   of	   short	   stature)	   and	   the	   biochemical	   deficiency	   (IGF1	  309 
SDS)	  in	  our	  cohort	  is	  striking.	  IGF1	  levels	  were	  measured	  at	  the	  6	  referral	  centres,	  hence	  310 
several	   different	   IGF1	   assays	  were	   used.	  However,	   taking	   this	   limitation	   into	   account,	  311 
many	   of	   the	  most	   severely	   affected	   patients	   (height	   SDS	   -­‐4.0	   to	   -­‐5.9)	   have	   IGF1	   SDS	  312 
values,	  which	  are	  in	  the	  normal	  range	  or	  mildly	  reduced	  (-­‐2.9	  to	  -­‐1.4).	  The	  reason	  for	  this	  313 
discrepancy	   is	   unclear	   but	   may	   be	   a	   result	   of	   additive	   molecular	   defects	   in	   other	  314 
proteins	  downstream	   from	   the	  GHR	   resulting	   in	  a	  greater	  degree	  of	   short	   stature	  e.g.	  315 
the	   IGF1	   receptor	   or	   signalling	  molecules	   of	   RAS-­‐MAPkinase	   pathway	   and/or	   the	   PI3-­‐316 
K/Akt	   pathway.	   Other	   genetic	   and/or	   environmental	   factors	   involved	   in	   the	   GHR	  317 
processing,	   trafficking	   and	   receptor	   degradation	   pathways	  may	   also	   be	   implicated	   18.	  318 
The	   use	   of	   different,	   rather	   than	   standardized	   /	   centralized	   IGF-­‐1	   assays,	   may	   also	  319 
contribute	  to	  the	  observed	  discrepancy.	  320 
	  321 
The	  majority	   of	   reported	   patients	  with	  GHR	   6Ψ	  mutations	   are	   of	   Pakistani	   origin	   and	  322 
previous	  work	  by	  our	  group	  suggests	   the	  presence	  of	  a	   common	  ancestor18.	  Although	  323 
most	  of	  the	  families	  were	  reportedly	  unrelated,	  patients	  J1	  and	  A5	  were	  distant	  cousins.	  	  324 
	  325 
Response	  to	  rhIGF1	  therapy	  has	  not	  been	  previously	  assessed	  in	  patients	  with	  6Ψ	  GHR	  326 
mutations.	   Given	   that	   a	   number	   of	   patients	   in	   our	   cohort	   had	   a	  mild	   degree	   of	   IGF1	  327 
deficiency,	  it	  is	  tempting	  to	  speculate	  that	  the	  response	  to	  rhIGF1	  therapy	  would	  be	  sub-­‐328 
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optimal.	   However,	   the	   first	   year	   growth	   response,	   demonstrated	   by	   the	   significant	  329 
increase	  in	  height	  velocity	  (baseline	  HV	  4.7	  ±	  1.1	  cm/yr	  and	  year	  1	  HV	  7.4	  ±	  1.8	  cm/yr)	  in	  330 
our	  patients,	  was	  comparable	  to	  that	  reported	  in	  patients	  with	  other	  homozygous	  GHR	  331 
defects	  (baseline	  HV	  4.7	  ±	  1.3	  cm/yr	  and	  year	  1	  HV	  8.2	  ±	  0.8	  m/yr)	  33	  and	  other	  patients	  332 
with	  severe	  IGF1	  deficiency	  (baseline	  values	  2.8-­‐4.0	  cm/yr	  and	  year	  1	  HV	  7.4-­‐8.5	  cm/yr)	  333 
34-­‐37.	  Contrary	  to	  reported	  data	  from	  a	   large	  European	  cohort	  of	  patients	  on	  rhIGF1	  38,	  334 
the	  increase	  in	  1st	  year	  height	  velocity	  in	  our	  cohort	  did	  not	  correlate	  with	  age	  of	  rhIGF1	  335 
initiation	   or	   lower	   baseline	   height	   SDS.	   Furthermore,	   similar	   to	   other	   studies34,35,	   the	  336 
growth-­‐promoting	   effects	   of	   rhIGF1	   appeared	   to	   persist,	   as	   there	   was	   a	   significant	  337 
improvement	   in	  height	  SDS	  at	  year	  3	  of	   treatment.	  The	  mean	  change	   in	  height	  SDS	   in	  338 
our	  cohort	   following	  5	  years	  of	   treatment	  was	  1.4	  ±	  0.9	  and	   is	  comparable	  to	  another	  339 
published	   study	   of	   patients	   with	   GHI	   (mean	   change	   1.4	   after	   6	   years	   of	   therapy)	   36.	  340 
Similar	   to	   other	   studies34,35,	   our	   patients	  who	  had	   completed	   rhIGF1	   therapy,	   did	   not	  341 
achieve	  adult	  heights	   in	   the	  normal	   range.	  However,	   the	  AH	  was	  higher	   than	   the	  pre-­‐342 
treatment	   height	   SDS	   and	   indicates	   a	   positive	   effect	   of	   rhIGF1	   on	   growth	   outcome34.	  343 
Overall,	  the	  effect	  of	  rhIGF1	  therapy	  on	  height	  outcomes	  in	  our	  cohort	  was	  encouraging.	  	  344 
	  345 
Only	  one	  subject,	  D2,	  responded	  during	  the	  IGFGT.	  His	  height	  was	  -­‐4.9	  SDS	  and	  he	  had	  346 
normal	  facial	  features.	  Although	  he	  was	  treated	  with	  rhIGF1	  therapy,	  data	  on	  his	  clinical	  347 
course	  and	  response	  to	  treatment	  was	  unavailable,	  hence	  he	  was	  not	  included	  in	  the	  15	  348 
treated	  patients	  described	  in	  this	  manuscript.	  349 
	  350 
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In	   summary,	   the	  homozygous	   intronic	  6Ψ	  GHR	  mutation	  caused	  both	  severe	  and	  mild	  351 
GHI	  phenotypes,	  even	  in	  individuals	  within	  the	  same	  kindred.	  The	  presence	  or	  absence	  352 
of	  abnormal	  facial	  features	  did	  not	  correlate	  with	  either	  the	  degree	  of	  short	  stature	  or	  353 
the	   biochemical	   abnormalities.	   There	  was	   often	   a	  mismatch	   between	   the	   clinical	   and	  354 
biochemical	  features	  in	  individual	  patients.	  rhIGF1	  treatment	  improved	  long-­‐term	  height	  355 
outcomes	   as	   has	   been	   demonstrated	   in	   GHI	   patients	   with	   other	   homozygous	   GHR	  356 
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Table	   1:	   Clinical	   and	   auxological	   details	   of	   the	   patients	   with	   homozygous	   GHR	  501 
pseudoexon	  (6ψ)	  mutations	  	  	  502 
	   503 
	   504 
























1*	   1.3	   M	   -­‐1.7	   -­‐4.9	   -­‐0.2	   -­‐2.2	   Pak/+	   No	  
2*	   3.7	   M	   -­‐5.9	   -­‐2.0	   0.3	   -­‐2.2	   Pak/+	   No	  
3*	   8.3	   M	   -­‐3.3	   -­‐0.4	   NK	   -­‐1.6	   Pak/+	   No	  
4*	   3.8	   M	   -­‐3.6	   -­‐0.5	   -­‐0.1	   -­‐1.6	   Pak/+	   No	  
5*	   1.2	   F	   -­‐4.4	   +1.8	   0.7	   -­‐2.4	   Pak/+	   No	  
6	   2.5	   F	   -­‐4.4	   -­‐0.1	   -­‐1.8	   NK	   Pak/+	   Yes	  
B	   1*	   1.6	   F	   -­‐5.6	   -­‐2.4	   -­‐1.4	   -­‐1.4	   Pak/+	   Yes	  





1*	   3.3	   M	   -­‐4.9	   0.1	   NK	   NK	   Pak/+	   No	  
2*	   8.1	   M	   -­‐3.3	   -­‐2.4	   -­‐1.5	   NK	   Pak/+	   No	  
E	  
1*	   5.4	   F	   -­‐3.5	   0.02	   NK	   NK	   Pak/+	   No	  
2*	   NK	   F	   -­‐4.0	   NK	   NK	   NK	   Pak/+	   No	  
 25 
F	   1	   7.0	   M	   -­‐4.2	   -­‐0.5	   -­‐0.5	   -­‐0.9	   Pak/+	   No	  
G	  
1	   2.6	   M	   -­‐3.8	   -­‐2.9	   -­‐2.9	   -­‐1.3	   Pak/+	   Yes	  
2	   3.7	   F	   -­‐4.2	   -­‐0.9	   0.1	   0.7	   Pak/+	   Yes	  
H	  
1	   5.7	   M	   -­‐3.0	   -­‐0.7	   0.7	   -­‐0.7	   Pak/+	   Yes	  
2	   1.5	   F	   -­‐4.7	   -­‐1.2	   NK	   -­‐0.7	   Pak/+	   Yes	  
I	   1	   2.3	   F	   -­‐4.3	   -­‐1.7	   -­‐1.7	   -­‐1.6	   Ind/-­‐	   Yes	  
J	   1	   5.3	   F	   -­‐4.0	   0.4	   0.1	   -­‐1.6	   Pak/+	   Yes	  
K	   1	   4.3	   F	   -­‐4.1	   -­‐0.2	   -­‐0.3	   -­‐0.9	   Pak/+	   Yes	  
	  506 
*	   Patients	   previously	   reported16,18.	   Age	   and	   Height	   SDS	   are	   at	   presentation.	   NK,	   not	   known;	   +,	   	   parents	  507 
consanguineous;	   -­‐,	   parents	   not	   consanguineous;	   Pak,	   Pakistani;	   Ind,	   Indian;	   GHI	   facial	   features:	   frontal	  508 
































1*	   11.0	   10.0	   -­‐2.5	   23.0/24.0	   -­‐6.0	  
2*	   6.0	   14.3	   -­‐2.5	   21.0/26.0	   -­‐8.9	  
3*	   1.8	   53.3	   -­‐1.7	   29.0/36.0	   -­‐2.9	  
4*	   17.5	   90.0	   -­‐2.0	   20.0/20.0	   -­‐3.4	  
5*	   0.1	   18.8	   -­‐2.2	   ND	   -­‐1.72	  
	  	  	  	  	  	  	  6	   3.4	   26.7	   NK	   ND	   ND	  
B	   1*	   13.0	   >33.3	   -­‐2.3	   6.9/7.6	   -­‐2.4	  
C	   1*	   0.6	   NK	   NK	   NK	   NK	  
D	  
1*	   10.2	   15.4	   -­‐2.3	   36.0/41.0	   -­‐2.6	  
2*	   0.3	   28.4	   -­‐0.7	   132.0/255.0*	   -­‐1.6	  
E	   1*	   2.5	   27.0	   -­‐1.0	   ND	   -­‐2.3	  
 27 
2*	   8.3	   37.7	   -­‐1.4	   ND	   -­‐2.3	  




1	   4.0	   >33.0	   -­‐2.3	   63.3/16.8	   ND	  
2	   16.9	   33.3	   -­‐2.5	   ND	   ND	  
H	  
1	   17.5	   90.0	   -­‐2.9	   1.5/8.4	   -­‐2.4	  
2	   0.1	   18.8	   -­‐3.1	   ND	   ND	  
I	   1	   3.4	   26.7	   -­‐2.1	   ND	   ND	  
J	   1	   19.3	   >40.0	   -­‐6.8	   <25.0/<25.0	   ND	  
K	   1	   0.6	   NK	   -­‐4.0	   <22.9/<22.9	   -­‐2.4	  







Figure	   1.	   Patient	   with	   homozygous	   GHR	   pseudoexon	   mutation	   and	   normal	   facial	  529 
features.	  530 
A	   patient	   with	   the	   homozygous	  GHR	   pseudoexon	  mutation	   but	   no	   dysmorphic	   facial	  531 






                           Pre-treatment      1st yr              2nd yr              3rd yr               



















                     Median            4.5                     7.2                      5.9                       5.7 
                       IQR              3.7-5.5              6.3-9.1                4.8-6.8               4.3-6.3 






Figure	  2.	  Height	  velocity	  at	  four	  different	  time	  points	  during	  treatment	  with	  rhIGF1.	  539 
Box	   and	   whisker	   plots	   show	   the	   median,	   upper	   and	   lower	   quartiles	   and	   range;	   IQR,	  540 
interquartile	  range;	  n,	  number	  of	  patients	  data	  available/included	  for	  each	  time	  point;	  p	  541 
values	  calculated	  by	  ANOVA	  with	  Dunn-­‐Bonferroni	  post	  hoc	  pairwise	  comparison;	  *	  p=	  542 















                               Pre-treatment         1st yr              2nd yr         3rd yr               
                            Median                 -4.4                    -3.9                    -3.4                    -3.2 
                        IQR            -4.8 to -3.6       -4.6 to -2.8       -4.2 to -2.6        -4.1 to -2.2 





Figure	  3.	  Height	  SDS	  at	  four	  different	  time	  points	  during	  treatment	  with	  rhIGF1.	  547 
Box	   and	   whisker	   plots	   show	   the	   median,	   upper	   and	   lower	   quartiles	   and	   range;	   IQR,	  548 
interquartile	  range;	  n,	  number	  of	  patients	  data	  available/included	  for	  each	  time	  point;	  p	  549 
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Figure	   4.	   Individual	   growth	   curves	   for	   homozygous	   GHR	   pseudoexon	   mutation	  557 
patients	  who	  have	  completed	  rhIGF-­‐I	  therapy.	  	  558 
a.	   Individual	  growth	  and	  adult	  height	  data	  of	  8	  male	  patients,	   compared	  with	   the	  UK-­‐559 
WHO	  growth	  standards21-­‐23	  (upper	  shaded	  area;	  mean	  represents	  the	  50th	  centile;	  +2	  SD	  560 
represents	  the	  91st	  centile;	  -­‐2	  SD	  represents	  the	  2nd	  centile	  on	  the	  UK-­‐WHO	  charts)	  and	  561 
the	  mean	  ±2	  SD	  for	  height	  for	  untreated	  Laron	  syndrome	  patients	  (lower	  shaded	  area;	  562 
represents	  reference	  range	  for	  patients	  with	  presumed	  GH	  receptor	  abnormalities28).	  b.	  563 
Individual	   growth	   and	   adult	   height	   data	   of	   4	   female	   patients,	   compared	  with	   the	  UK-­‐564 
WHO	  growth	  standards21-­‐23	  (upper	  shaded	  area;	  mean	  represents	  the	  50th	  centile;	  +2	  SD	  565 
 33 
represents	  the	  91st	  centile;	  -­‐2	  SD	  represents	  the	  2nd	  centile	  on	  the	  UK-­‐WHO	  charts)	  and	  566 
the	  mean	  ±2	  SD	  for	  height	  for	  untreated	  Laron	  syndrome	  patients	  (lower	  shaded	  area;	  567 






















                 Median                     3.0                                           2.3 
                    IQR                    2.4 to 3.8                                 0.9 to 3.3  







Figure	  5.	  Difference	  between	  target	  height	  (TH)	  and	  heights	  pre-­‐	  and	  post-­‐treatment	  572 
with	  rhIGF1.	  573 
Box	  and	  Whisker	  Plot	   showing	  A:	  Difference	  between	   target	  height	   (TH)	   SDS	  and	  pre-­‐574 
treatment	  baseline	  height	  SDS	  and	  B:	  Difference	  between	  Target	  Height	  SDS	  and	  Height	  575 
SDS	  at	  final	  adult	  height	  (AH)	  or	  at	  latest	  assessment	  (LH)	  during	  treatment	  with	  rhIGF1	  576 
 34 
therapy.	   Box	   plots	   show	   the	   median,	   upper	   and	   lower	   quartiles	   and	   range;	   IQR=	  577 
interquartile	  range;	  p	  values	  calculated	  by	  student’s	  unpaired	  t-­‐test;	  *,	  p=0.02.	  578 
	  579 
